Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

被引：308

作者：

Moriyama, B. ^{[1
]}

Obeng, A. Owusu ^{[2
,3
,4
]}

Barbarino, J. ^{[5
]}

Penzak, S. R. ^{[6
]}

Henning, S. A. ^{[1
]}

Scott, S. A. ^{[2
,7
]}

Agundez, J. A. G. ^{[8
]}

Wingard, J. R. ^{[9
]}

McLeod, H. L. ^{[10
]}

Klein, T. E. ^{[5
]}

Cross, S. J. ^{[11
,12
]}

Caudle, K. E. ^{[11
]}

Walsh, T. J. ^{[13
,14
,15
]}

机构：

[1] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA

[2] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA

[3] Mt Sinai Hosp, Dept Pharm, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA

[5] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[6] Univ North Texas, Dept Pharmacotherapy, Syst Coll Pharm, Ft Worth, TX USA

[7] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[8] Univ Extremadura, Dept Pharmacol, Caceres, Spain

[9] Univ Florida, Coll Med, Gainesville, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Div Populat Sci, Tampa, FL USA

[11] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[12] Univ Tennessee, Coll Pharm, Dept Clin Pharm, Memphis, TN USA

[13] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Med, New York, NY 10021 USA

[14] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Pediat, New York, NY 10021 USA

[15] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Microbiol & Infect Dis, New York, NY 10021 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 01期

基金：

美国国家卫生研究院;

关键词：

INFECTIOUS-DISEASES SOCIETY; INTRAVENOUS VORICONAZOLE; PLASMA-CONCENTRATIONS; 2016; UPDATE; SAFETY; PHARMACOKINETICS; GENOTYPE; EFFICACY; VARIANT; POLYMORPHISMS;

D O I：

10.1002/cpt.583

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

引用

页码：45 / 51

页数：7

共 38 条

[1] Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications
Andes, David
Pascual, Andres
Marchetti, Oscar
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) : 24 - 34
[2] Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014
Chau, M. M.
Kong, D. C. M.
van Hal, S. J.
Urbancic, K.
Trubiano, J. A.
Cassumbhoy, M.
Wilkes, J.
Cooper, C. M.
Roberts, J. A.
Marriott, D. J. E.
Worth, L. J.
[J]. INTERNAL MEDICINE JOURNAL, 2014, 44 (12B) : 1364 - 1388
[3] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, DW
Ribaud, P
Milpied, N
Caillot, D
Herbrecht, R
Thiel, E
Haas, A
Ruhnke, M
Lode, H
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 563 - 571
[4] Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels
Gautier-Veyret, Elodie
Fonrose, Xavier
Tonini, Julia
Thiebaut-Bertrand, Anne
Bartoli, Mireille
Quesada, Jean-Louis
Bulabois, Claude-Eric
Cahn, Jean-Yves
Stanke-Labesque, Francoise
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 2305 - 2314
[5] Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
Geist, Marcus J. P.
Egerer, Gerlinde
Burhenne, Juergen
Mikus, Gerd
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 3227 - 3228
[6] Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration
Hafner, Verena
Czock, David
Burhenne, Juergen
Riedel, Klaus-Dieter
Bommer, Juergen
Mikus, Gerd
Machleidt, Christoph
Weinreich, Thomas
Haefeli, Walter E.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2596 - 2602
[7] Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis
Hamada, Yukihiro
Seto, Yoshinori
Yago, Kazuo
Kuroyama, Masakazu
[J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) : 501 - 507
[8] Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole
He, H. -R.
Sun, J. -Y.
Ren, X. -D.
Wang, T. -T.
Zhai, Y. -J.
Chen, S. -Y.
Dong, Y. -L.
Lu, J.
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (04) : 811 - 819
[9] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J. K.
Bishop, J. R.
Sangkuhl, K.
Mueller, D. J.
Ji, Y.
Leckband, S. G.
Leeder, J. S.
Graham, R. L.
Chiulli, D. L.
LLerena, A.
Skaar, T. C.
Scott, S. A.
Stingl, J. C.
Klein, T. E.
Caudle, K. E.
Gaedigk, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
[10] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Hicks, J. K.
Swen, J. J.
Thorn, C. F.
Sangkuhl, K.
Kharasch, E. D.
Ellingrod, V. L.
Skaar, T. C.
Mueller, D. J.
Gaedigk, A.
Stingl, J. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (05) : 402 - 408

← 1 2 3 4 →